About The Science
What this site is, who writes it, how the diagrams are drawn and the evidence graded, what it will not do, and how to reach the editorial team.
What this site is
The Science (formblendsscience.com) explains how GLP-1 and GIP/GLP-1 medicines work inside the body, one mechanism or one outcome trial per page, with a diagram drawn for each. It is part of the FormBlends network and is run by the FormBlends editorial team. FormBlends (formblends.com) operates a GLP-1 weight-management program that dispenses compounded semaglutide and tirzepatide, which are not FDA approved and are not interchangeable with brand products. That relationship is disclosed here and in the footer of every page so you can weigh it.
This site does not sell anything, does not take advertising and does not host user reviews. Where a page links to formblends.com, the link goes to a guide, a research report or a product page a reader might reasonably want next, and it is a plain link.
Who writes it
The FormBlends editorial team: writers and editors with a background in reading clinical and physiology literature. We do not name individual clinicians as authors or reviewers, and we do not attach "medically reviewed by" claims. If a page relies on a clinician's judgment rather than on a cited source, that is a defect and we want to hear about it.
How the diagrams are made
Every figure on this site is an original SVG drawn for the page from the cited papers and labels. None is a redrawn textbook figure or a stock illustration. Each carries a title and a long description for screen readers, uses inline colours that work on a white page, and follows one convention: a solid arrow or frame is a documented effect, a dashed one is proposed, debated or shown only in animals. Charts drawn to trial data use the published means; where a curve shape between data points is illustrative, the caption says so.
How the evidence is graded
Each mechanistic claim on this site is tied to a PubMed identifier or to an FDA label on Drugs@FDA. The interactive mechanism map grades every effect A to D by the kind of evidence behind it: A for a randomised human trial or a label statement derived from one, B for human physiology or cohort studies, C for animal or cell evidence, D for hypotheses and live disagreements. The grading page explains the scale and its limits. Where a mechanism is debated, the page says so rather than picking a side.
What this site will not do
It will not tell you whether a medicine is right for you, what dose to take, how to change a dose or when to stop. It will not describe compounded products as equivalent to approved ones. It will not fabricate a quotation, a reviewer or a review. It will not add rating schema to pages, and it only marks up questions that actually appear on the page.
Corrections and contact
If a citation is wrong, a number does not match its source, or a mechanism has been settled since a page was last updated, email hello@formblends.com with the page URL and the source. Every page shows the date it was last updated. Corrections are made on the page, not in a separate log.
Elsewhere in the network
Trial numbers with confidence intervals live at FormBlends Research. Every agent's approvals and label dosing are at GLP-1s Explained. Nutrition and training during treatment are at Weight Loss on GLP-1s. FormBlends' own overview is at formblends.com/science.
Sources (3)
Show the referencesHide
- Pyke C, Heller RS, Kirk RK, et al. GLP-1 receptor localization in monkey and human tissue. Endocrinology 2014. PubMed 24467746 Accessed September 4, 2026.
- Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 2018. PubMed 29617641 Accessed September 4, 2026.
- Drugs@FDA: FDA-approved drugs database Accessed September 4, 2026.